Dade Behring gets warning letter from FDA
This article was originally published in Clinica
The FDA has accused Dade Behring of failing to take corrective action over problems with preservatives which had resulted in the withdrawal of three loads of Chlamydia test kits. In addition, the FDA says in a warning letter to Dade Behring, the company was slow at processing complaints and problems were found with the sampling plan for reliability testing.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.